Phaseline

Companies › Remedy Plan

Remedy Plan: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RPT1G
Selective hyperbolic NAMPT inhibitor
NAMPTPhase 1Acute Myeloid LeukemiaDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07107126RPT1GPhase 1Acute Myeloid LeukemiaOncologyDec 2028

Targets

NAMPT (1)

Companies with the same targets

ORIC Pharmaceuticals Metro International Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.